AU2002953436A0 - A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis - Google Patents

A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Info

Publication number
AU2002953436A0
AU2002953436A0 AU2002953436A AU2002953436A AU2002953436A0 AU 2002953436 A0 AU2002953436 A0 AU 2002953436A0 AU 2002953436 A AU2002953436 A AU 2002953436A AU 2002953436 A AU2002953436 A AU 2002953436A AU 2002953436 A0 AU2002953436 A0 AU 2002953436A0
Authority
AU
Australia
Prior art keywords
malignancy
treating
via direct
subject via
mediated oncolysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002953436A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newcastle Innovation Ltd
Original Assignee
University of Newcastle Australia
Newcastle Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Newcastle Australia, Newcastle Innovation Ltd filed Critical University of Newcastle Australia
Priority to AU2002953436A priority Critical patent/AU2002953436A0/en
Publication of AU2002953436A0 publication Critical patent/AU2002953436A0/en
Priority to US10/539,219 priority patent/US7485292B2/en
Priority to EP03779569.7A priority patent/EP1581257B1/en
Priority to CA2510227A priority patent/CA2510227C/en
Priority to KR1020057011510A priority patent/KR101171295B1/ko
Priority to HK06103056.9A priority patent/HK1082194B/en
Priority to ES03779569.7T priority patent/ES2463678T3/es
Priority to NZ541230A priority patent/NZ541230A/en
Priority to PCT/AU2003/001688 priority patent/WO2004054613A1/en
Priority to CN2003801098083A priority patent/CN1784242B/zh
Priority to AU2003287773A priority patent/AU2003287773C1/en
Priority to JP2004559490A priority patent/JP2006517189A/ja
Priority to CN201110091011.1A priority patent/CN102166228B/zh
Priority to ZA200505389A priority patent/ZA200505389B/en
Priority to US12/365,120 priority patent/US20100062020A1/en
Priority to JP2011151340A priority patent/JP2012046489A/ja
Priority to HK11112125.0A priority patent/HK1157657B/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002953436A 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis Abandoned AU2002953436A0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AU2002953436A AU2002953436A0 (en) 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
ZA200505389A ZA200505389B (en) 2002-12-18 2003-12-18 A method of treating a malignancy in a subject viadirect picornaviral-medicated oncolysis
PCT/AU2003/001688 WO2004054613A1 (en) 2002-12-18 2003-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
AU2003287773A AU2003287773C1 (en) 2002-12-18 2003-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
CA2510227A CA2510227C (en) 2002-12-18 2003-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
KR1020057011510A KR101171295B1 (ko) 2002-12-18 2003-12-18 직접 피코르나비랄-매개 종양 용해를 통한 피검체의 악성종양 치료방법
HK06103056.9A HK1082194B (en) 2002-12-18 2003-12-18 Composition comprising echovirus ev1 and its use
ES03779569.7T ES2463678T3 (es) 2002-12-18 2003-12-18 Composición que comprende echovirus EV1 y su uso
NZ541230A NZ541230A (en) 2002-12-18 2003-12-18 A method of treating abnormal cells in a non-human mammal using a echovirus which recognise alpha-1 beta-2 for infecitvity of the cells
US10/539,219 US7485292B2 (en) 2002-12-18 2003-12-18 Method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
CN2003801098083A CN1784242B (zh) 2002-12-18 2003-12-18 通过小核糖核酸病毒直接介导的溶瘤作用治疗受试者恶性肿瘤的方法
EP03779569.7A EP1581257B1 (en) 2002-12-18 2003-12-18 Composition comprising echovirus EV1 and its use
JP2004559490A JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法
CN201110091011.1A CN102166228B (zh) 2002-12-18 2003-12-18 通过小核糖核酸病毒直接介导的溶瘤作用治疗受试者恶性肿瘤的方法
US12/365,120 US20100062020A1 (en) 2002-12-18 2009-02-03 Method of Treating a Malignancy in a Subject Via Direct Picornaviral-Mediated Oncolysis
JP2011151340A JP2012046489A (ja) 2002-12-18 2011-07-08 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法
HK11112125.0A HK1157657B (en) 2002-12-18 2011-11-09 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2002953436A AU2002953436A0 (en) 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Publications (1)

Publication Number Publication Date
AU2002953436A0 true AU2002953436A0 (en) 2003-01-09

Family

ID=30004521

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002953436A Abandoned AU2002953436A0 (en) 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Country Status (11)

Country Link
US (2) US7485292B2 (enExample)
EP (1) EP1581257B1 (enExample)
JP (2) JP2006517189A (enExample)
KR (1) KR101171295B1 (enExample)
CN (2) CN1784242B (enExample)
AU (1) AU2002953436A0 (enExample)
CA (1) CA2510227C (enExample)
ES (1) ES2463678T3 (enExample)
NZ (1) NZ541230A (enExample)
WO (1) WO2004054613A1 (enExample)
ZA (1) ZA200505389B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
KR101295733B1 (ko) 2004-08-20 2013-08-13 비랄리틱스 리미티드 혈액암의 치료방법 및 조성물
CN102166218A (zh) * 2005-01-17 2011-08-31 溶瘤病毒有限公司 治疗肿瘤的方法和组合物
WO2013157648A1 (ja) 2012-04-19 2013-10-24 国立大学法人九州大学 医薬組成物
EP2826856B9 (en) 2013-07-16 2016-05-04 Sia Latima Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
RU2682762C2 (ru) * 2013-11-27 2019-03-21 Общество С Ограниченной Ответственностью "Панацела Лабс" Улучшенный вектор, экспрессирующий toll-подобный рецептор и агонист, и применение в терапии рака
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
CN103981152B (zh) * 2014-04-16 2015-01-21 武汉博威德生物技术有限公司 一种柯萨奇病毒及其制备抗肿瘤药物之应用
MX428707B (es) 2016-09-27 2025-11-13 Sator Therapeutics LLC Virus oncoliticos optimizados y usos de los mismos.
WO2018182014A1 (ja) 2017-03-31 2018-10-04 久修 緒方 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
CA3117924A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113421A (en) * 1978-02-24 1979-09-05 Fumiaki Taguchi Large scale cultivation of virus
US5585254A (en) 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
WO1990012087A1 (en) 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2115991A1 (en) 1991-06-24 1993-01-07 Eckard Wimmer De novo cell-free synthesis of picornavirus
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
DK0689447T3 (da) 1993-02-16 1999-10-18 Onyx Pharma Inc Cytopatiske vira til behandling af og profylakse for neoplasia
ES2310580T3 (es) 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
EP1905304A3 (en) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1061806A4 (en) 1998-03-12 2001-09-12 Univ Pennsylvania PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES
US6060316A (en) 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
EP1150696B1 (en) 1999-02-05 2006-05-10 Arch Development Corporation Genetically engineered herpes virus for the treatment of tumours
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
AU2005201079C1 (en) 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
DE19939095A1 (de) 1999-08-18 2001-02-22 Univ Eberhard Karls Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer
AU782402B2 (en) 1999-09-17 2005-07-28 Wellstat Biologics Corporation Oncolytic virus
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
WO2001036650A2 (en) 1999-11-15 2001-05-25 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU770517B2 (en) 1999-11-25 2004-02-26 Viralytics Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2004202292B2 (en) 1999-11-25 2007-06-14 Viralytics Limited Method of Treating a Malignancy in a Subject
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20020071832A1 (en) 2000-06-01 2002-06-13 Yuman Fong Use of mutant herpes viruses and anticancer agents in the treatment of cancer
WO2002043647A2 (en) 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
US20020146828A1 (en) * 2001-01-05 2002-10-10 John Hural Microparticles and methods for delivery of recombinant viral vaccines
WO2002087625A1 (en) 2001-05-02 2002-11-07 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
EP2140879A1 (en) 2001-05-09 2010-01-06 M'S Science Corporation Composition and method for treating cancer using herpes virus
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
CA2352439A1 (en) 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
JP2004536607A (ja) 2001-07-23 2004-12-09 オニックス ファーマシューティカルズ，インコーポレイティド 標的化されたヒト癌細胞において選択的に複製するウイルス変異体
AU2003216502B2 (en) 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
WO2003082200A2 (en) 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
NZ536102A (en) 2002-05-09 2008-01-31 Oncolytics Biotech Inc Oncolytic viruses, in particular reovirus, for reducing pain associated with proliferative disorders, particularly with the growth of a solid tumour mass
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005002607A2 (en) 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
WO2005007824A2 (en) 2003-07-08 2005-01-27 Arizona Board Of Regents Mutants of vaccinia virus as oncolytic agents
DK1668025T3 (da) 2003-09-26 2014-08-25 Novartis Ag Seneca Valley-virusbaserede præparater og fremgangsmåder til behandling af sygdom
CN101027394A (zh) 2004-03-11 2007-08-29 维若塔歌私人有限公司 修饰的溶瘤病毒
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2006047301A2 (en) 2004-10-21 2006-05-04 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells

Also Published As

Publication number Publication date
HK1082194A1 (en) 2006-06-02
JP2006517189A (ja) 2006-07-20
CA2510227C (en) 2015-03-31
ZA200505389B (en) 2006-09-27
KR20050115859A (ko) 2005-12-08
US20060134778A1 (en) 2006-06-22
CN1784242A (zh) 2006-06-07
US7485292B2 (en) 2009-02-03
KR101171295B1 (ko) 2012-08-07
EP1581257A1 (en) 2005-10-05
US20100062020A1 (en) 2010-03-11
EP1581257B1 (en) 2014-04-30
ES2463678T3 (es) 2014-05-28
CN102166228B (zh) 2014-02-19
EP1581257A4 (en) 2007-10-17
WO2004054613A1 (en) 2004-07-01
CA2510227A1 (en) 2004-07-01
CN1784242B (zh) 2011-06-08
HK1157657A1 (en) 2012-07-06
CN102166228A (zh) 2011-08-31
NZ541230A (en) 2008-04-30
JP2012046489A (ja) 2012-03-08

Similar Documents

Publication Publication Date Title
AU2003226301A8 (en) Method of treating cancer
EP1565644A4 (en) METHOD AND SYSTEM FOR TREATING DRILLING HOLES
AU2003256847A8 (en) Method of treating cancer
AU2003280004A1 (en) Hair treatment method
AU2003293333A8 (en) Method of treating cancers
IL164352A0 (en) Methods for treating tweak-related conditions
EP1471902A4 (en) METHOD FOR TREATING HEARING LOSS
IL164219A0 (en) Method for treating and preventing hyparathyroidism
AUPS160602A0 (en) Therapeutic method
AU2003256526A1 (en) Arrangements and methods for treating a subject
AU2002338191A1 (en) Surface treatment system and surface treatment method
AU2003286421A1 (en) Polishing method
AU2003227414A1 (en) Polishing method
GB0201498D0 (en) Materials and methods for treating cancer
IL163835A0 (en) Method for treating carbonaceous materials
AUPS201002A0 (en) Method of treating shellfish
AU2002359074A1 (en) Surface treatment system and method
AU2002951011A0 (en) Water treatment process
IL147898A0 (en) Auger effect-based cancer therapy method
AU2003213109A1 (en) Method for treating cellulite
GB2392400B (en) Waste treatment process
GB0223325D0 (en) Treating cancer
AU2002100820A4 (en) Method and means relating to clothing
AU2003261951A1 (en) Medicinal composition and method for treating malignant tumor and utilization thereof
GB2406340B (en) Fabric treatment method